- CRISPR Therapeutics (NASDAQ:CRSP) and collaboration partner Viacyte announce encouraging data on the use of CRISPR/Cas9 to edit a pluripotent stem cell line called CyT49 that is being used to generate islet progenitor cells for type 1 diabetes (T1D) clinical trials. The data were presented at the Annual Meeting of the European Association for the Study of Diabetes in Barcelona.
- The results showed that CyT49 can be successfully edited with CRISPR. The ultimate goal is the creation of an immune system-evading cell replacement therapy for T1D, an autoimmune disorder in which the body's immune system destroys certain cells in the pancreas that make insulin.
- The companies are currently evaluating a preclinical-stage candidate.